Structures by: Glidewell C.
Total: 1 449
Bis(2-aminoethyl)amine-3,5-dihydroxybenzoic acid (1/2)
C4H15N3,2(C7H5O4)
Acta Crystallographica Section B (2000) 56, 1 68-84
a=8.2469(7)Å b=10.527(2)Å c=23.052(3)Å
α=90.00° β=98.144(9)° γ=90.00°
Tris(2-aminoethyl)amine-4,4'-biphenol-methanol (1/3/1)
2(C6H19N4),5(C12H10O2),C12H8O2,2(CH4O)
Acta Crystallographica Section B (2000) 56, 1 68-84
a=10.0041(2)Å b=41.5502(7)Å c=10.27150(10)Å
α=90.00° β=112.7460(10)° γ=90.00°
2-Iodo-N-(4-nitrobenzyl)aniline
C13H11IN2O2
Acta Crystallographica Section B (2004) 60, 4 472-480
a=16.1564(6)Å b=9.3589(3)Å c=8.3326(3)Å
α=90.00° β=96.3330(10)° γ=90.00°
3-Iodo-N-(4-nitrobenzyl))aniline
C13H11IN2O2
Acta Crystallographica Section B (2004) 60, 4 472-480
a=7.0966(2)Å b=12.5908(4)Å c=13.8360(6)Å
α=90.00° β=90.00° γ=90.00°
4-Iodo-N-(3-nitrobenzyl))aniline
C13H11IN2O2
Acta Crystallographica Section B (2004) 60, 4 472-480
a=21.2778(15)Å b=8.1809(5)Å c=7.2793(4)Å
α=90.00° β=94.316(2)° γ=90.00°
2,2,3,3',4,4'-Hexaacetato-6,6'-bis-O-(4-toluenesulfonyl)-α,α'-trehalose
C38H46O21S2
Acta Crystallographica Section B (2004) 60, 4 461-471
a=18.1484(9)Å b=21.1046(9)Å c=23.4224(14)Å
α=90.00° β=90.00° γ=90.00°
2-Iodo-N-(2-nitrobenzyl))aniline
C13H11IN2O2
Acta Crystallographica Section B (2004) 60, 4 472-480
a=8.16850(10)Å b=10.8834(2)Å c=15.4372(2)Å
α=76.9219(9)° β=80.0727(7)° γ=74.2167(7)°
2,2,3,3',4,4'-Hexaacetato-6,6'-bis-O-methylsulfonyl-α,α'-trehalose
C26H38O21S2
Acta Crystallographica Section B (2004) 60, 4 461-471
a=21.3279(8)Å b=8.9299(4)Å c=8.8382(4)Å
α=90.00° β=99.4537(17)° γ=90.00°
2,2,3,3'-Tetraacetato-6,6'-bis(N-acetylamino)-α,α'-trehalose dihydrate
C24H36N2O15,2(H2O)
Acta Crystallographica Section B (2004) 60, 4 461-471
a=8.8385(2)Å b=21.8363(8)Å c=8.0831(2)Å
α=90.00° β=90.00° γ=90.00°
2,2,3,3',4,4'-Hexaacetato-6,6'-diazido-α,α'-trehalose ethanol solvate
C24H32N6O15,0.35(C2H6O)
Acta Crystallographica Section B (2004) 60, 4 461-471
a=12.2281(4)Å b=15.5803(6)Å c=18.1066(8)Å
α=90.00° β=90.00° γ=90.00°
N^4^-(Cyclohexyl)-N^4^-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
C12H18N6
Acta Crystallographica Section B (2008) 64, 5 610-622
a=11.2407(10)Å b=7.3654(5)Å c=15.8178(12)Å
α=90.00° β=106.005(7)° γ=90.00°
N^4^-(3-Chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
C11H9ClN6
Acta Crystallographica Section B (2008) 64, 5 610-622
a=11.1960(8)Å b=8.5040(8)Å c=13.3815(12)Å
α=90.00° β=120.674(5)° γ=90.00°
N^4^-Methyl-N^4^-phenyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
C12H12N6
Acta Crystallographica Section B (2008) 64, 5 610-622
a=10.6661(12)Å b=7.7279(9)Å c=14.359(2)Å
α=90.00° β=100.071(7)° γ=90.00°
2-[4-(6-Amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]ethanol
C11H17N7O
Acta Crystallographica Section B (2008) 64, 5 610-622
a=7.0297(9)Å b=13.859(3)Å c=25.766(6)Å
α=90.00° β=90.00° γ=90.00°
N^4^-(4-Methoxyphenyl)-N^4^-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine hemihydrate
2(C13H14N6O),H2O
Acta Crystallographica Section B (2008) 64, 5 610-622
a=8.9516(5)Å b=12.0627(7)Å c=12.9053(7)Å
α=91.612(4)° β=92.065(3)° γ=95.259(5)°
C11H15ClN4O
C11H15ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=5.907(2)Å b=10.398(3)Å c=10.801(2)Å
α=110.86(3)° β=94.19(2)° γ=96.00(3)°
C9H13ClN4O
C9H13ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=11.328(3)Å b=8.0810(4)Å c=11.3849(12)Å
α=90.00° β=98.709(14)° γ=90.00°
C9H11ClN4O2
C9H11ClN4O2
Acta Crystallographica Section B (2008) 64, 5 596-609
a=7.3540(5)Å b=8.2910(13)Å c=17.276(3)Å
α=90.00° β=97.962(9)° γ=90.00°
C12H17ClN4O
C12H17ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=8.5722(6)Å b=8.7195(5)Å c=8.7681(7)Å
α=82.598(6)° β=82.701(5)° γ=88.645(5)°
C14H15ClN4O
C14H15ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=7.9897(5)Å b=8.0922(4)Å c=11.2786(7)Å
α=91.602(4)° β=107.220(5)° γ=91.776(5)°
C12H11ClN4O
C12H11ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=7.0568(7)Å b=8.211(2)Å c=10.565(3)Å
α=84.590(16)° β=82.363(14)° γ=78.687(14)°
C12H11ClN4O
C12H11ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=6.9938(6)Å b=7.9544(10)Å c=10.7507(14)Å
α=81.191(11)° β=82.469(12)° γ=87.333(10)°
C15H12ClN5O
C15H12ClN5O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=7.5716(7)Å b=16.6432(18)Å c=10.9450(7)Å
α=90.00° β=93.549(6)° γ=90.00°
C18H15ClN4O
C18H15ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=6.5520(11)Å b=11.1012(7)Å c=11.4111(4)Å
α=79.958(5)° β=84.802(9)° γ=77.009(9)°
C11H16ClN5O2
C11H16ClN5O2
Acta Crystallographica Section B (2008) 64, 5 596-609
a=7.2147(6)Å b=8.8563(10)Å c=10.2855(12)Å
α=84.856(10)° β=85.296(10)° γ=79.092(7)°
C10H13ClN4O
C10H13ClN4O
Acta Crystallographica Section B (2008) 64, 5 596-609
a=14.4681(17)Å b=11.1378(17)Å c=7.4534(7)Å
α=90.00° β=116.535(7)° γ=90.00°
N^4^-Methyl-N^4^-(4-phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine monohydrate
C13H14N6,H2O
Acta Crystallographica Section B (2008) 64, 5 610-622
a=16.5577(12)Å b=8.6833(3)Å c=18.4640(13)Å
α=90.00° β=90.00° γ=90.00°
N^4^-Ethyl-N^4^-phenyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine hemihydrate
C13H14N6,0.5(H2O)
Acta Crystallographica Section B (2008) 64, 5 610-622
a=17.642(3)Å b=18.278(3)Å c=8.3034(18)Å
α=90.00° β=103.512(17)° γ=90.00°
Phenylphosphonic acid--4,4'-bipyridyl (1/1).
C16H15N2O3P
Acta Crystallographica Section B (1998) 54, 2 129-138
a=6.9026(8)Å b=9.7086(9)Å c=12.201(2)Å
α=77.138(9)° β=74.345(10)° γ=75.477(8)°
Phenylphosphonic acid--piperazine (2/1)
C16H24N2O6P2
Acta Crystallographica Section B (1998) 54, 2 129-138
a=6.0042(9)Å b=19.746(3)Å c=8.651(2)Å
α=90.00° β=105.63(2)° γ=90.00°
Phenylphosphonic acid--1,4-diazabicyclo[2.2.2]octane (2/1)
C18H26N2O6P2
Acta Crystallographica Section B (1998) 54, 2 129-138
a=6.3607(3)Å b=21.8300(11)Å c=14.5965(9)Å
α=90.00° β=92.558(6)° γ=90.00°
4,4'-Thiodiphenol-1,4,8,11-tetraazacyclotetradecane (2/1)
C34H44N4O4S2
Acta Crystallographica Section B (1998) 54, 2 139-150
a=11.1602(12)Å b=10.8084(12)Å c=14.001(2)Å
α=90.00° β=103.127(10)° γ=90.00°
4,4'-Sulfonyldiphenol-1,4,8,11-tetraazacyclotetradecane (2/1)
C34H44N4O8S2
Acta Crystallographica Section B (1998) 54, 2 139-150
a=10.9345(10)Å b=11.0060(10)Å c=14.350(2)Å
α=79.532(10)° β=86.739(10)° γ=87.471(10)°
1,1,1-Tris(4-hydroxyphenyl)ethane-1,4,8,11-tetraazacyclotetradecane-methanol (2/1/1)
C51H64N4O7
Acta Crystallographica Section B (1998) 54, 2 139-150
a=8.2208(11)Å b=16.245(2)Å c=17.337(2)Å
α=81.694(13)° β=89.656(14)° γ=86.468(12)°
4,4'-Biphenol--1,2-diaminoethane--methanol (2/1/1)
C27H32N2O5
Acta Crystallographica Section B (1998) 54, 2 151-161
a=9.4592(7)Å b=10.6311(10)Å c=12.2085(14)Å
α=91.812(9)° β=93.091(6)° γ=90.652(6)°
4,4'-Biphenol--1,2-diaminoethane (1/1)
(C12H10O2).(C2H8N2)
Acta Crystallographica Section B (1998) 54, 2 151-161
a=8.2121(5)Å b=5.3401(3)Å c=14.6014(9)Å
α=90.00° β=99.962(7)° γ=90.00°
1,1,1-Tris(4-hydroxyphenyl)ethane--1,2-diaminoethane (2/1).
2(C20H18O3).(C2H8N2)
Acta Crystallographica Section B (1998) 54, 3 330-338
a=10.9430(12)Å b=11.1075(12)Å c=15.249(2)Å
α=98.672(15)° β=96.312(10)° γ=98.377(13)°
3-Amino-1<i>H</i>-pyrazol-2-ium 3,5-dinitrobenzoate monohydrate
C7H3N2O6,C3H6N3,H2O
Acta Crystallographica Section E (2021) 77, 1 34-41
a=6.6864(7)Å b=8.1857(9)Å c=12.6490(10)Å
α=79.424(9)° β=85.583(9)° γ=75.586(9)°
Bis(3-amino-1<i>H</i>-pyrazol-2-ium) fumarate—–fumaric acid (1/1) 2C~3~H~6~N~3~^+^\χdotC~4~H~2~O~4~^2-^\χdotC~4~H~4~O~4~, (II). The reaction of 3-amino-1<i>H</i>-pyrazole with a dilute solution of nitric acid in methanol yields an second, orthorhombic polymorph of 3-amino-1<i>H</i>-pyrazol-2-ium nitrate, C~3~H~6~N~3~^+^\χdotNO~3~^-^
2(C3H6N3),C4H2O42,C4H4O4
Acta Crystallographica Section E (2021) 77, 1 34-41
a=8.5410(4)Å b=14.0507(7)Å c=7.5137(4)Å
α=90° β=98.827(6)° γ=90°
3-Amino-1<i>H</i>-pyrazol-2-ium nitrate
C3H6N3,NO3
Acta Crystallographica Section E (2021) 77, 1 34-41
a=7.2700(10)Å b=9.907(2)Å c=8.551(2)Å
α=90° β=90° γ=90°
1-(4-Fluorobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19FN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=7.3286(6)Å b=11.3388(7)Å c=20.3040(10)Å
α=90° β=90° γ=90°
1-(4-Iodobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19IN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=10.9626(5)Å b=11.3258(6)Å c=14.8234(7)Å
α=90° β=104.520(5)° γ=90°
1-(4-Chlorobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19ClN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=29.7690(10)Å b=11.3173(4)Å c=20.4028(8)Å
α=90° β=90° γ=90°
1-(2-Fluorobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19FN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=7.4510(10)Å b=11.199(3)Å c=19.138(5)Å
α=90° β=99.59(2)° γ=90°
1-(4-Bromobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19BrN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=15.0779(7)Å b=11.2868(6)Å c=20.5297(9)Å
α=90° β=90° γ=90°
1-(3-Iodobenzoyl)-4-(2-methoxyphenyl)piperazine
C18H19IN2O2
Acta Crystallographica Section E (2021) 77, 1 5-13
a=7.4528(4)Å b=17.1306(9)Å c=27.9030(10)Å
α=90° β=90° γ=90°
Diethyl (<i>RS</i>)-2-[(4-chlorophenyl)(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazol-4-yl)methyl]propanedioate
C24H25ClN2O5
Acta Crystallographica Section E (2020) 76, 10 1605-1610
a=13.5609(8)Å b=20.2800(10)Å c=17.7280(10)Å
α=90° β=95.363(5)° γ=90°
Diethyl (<i>RS</i>)-2-[(4-bromophenyl)(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazol-4-yl)methyl]propanedioate
C24H25BrN2O5
Acta Crystallographica Section E (2020) 76, 10 1605-1610
a=13.5644(5)Å b=20.3405(7)Å c=17.4818(8)Å
α=90° β=94.858(4)° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 4-chlorobenzoate
C11H17N2O,C7H4ClO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.4010(10)Å b=7.8880(10)Å c=15.410(3)Å
α=100.28(2)° β=94.400(10)° γ=94.140(10)°
4-(2-Methoxyphenyl)piperazin-1-ium 4-bromobenzoate
C11H17N2O,C7H4BrO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.4313(5)Å b=7.9163(5)Å c=15.5212(9)Å
α=101.565(5)° β=94.780(5)° γ=92.691(5)°
4-(2-Methoxyphenyl)piperazin-1-ium 4-iodobenzoate
C11H17N2O,C7H4IO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.1129(4)Å b=11.2722(7)Å c=12.5923(8)Å
α=69.852(5)° β=74.681(5)° γ=79.121(5)°
4-(2-Methoxyphenyl)piperazin-1-ium 2-fluorobenzoate
C11H17N2O,C7H4FO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=19.9400(10)Å b=10.2705(7)Å c=9.0148(7)Å
α=90° β=109.663(8)° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 2-chlorobenzoate
C11H17N2O,C7H4ClO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.9974(8)Å b=27.611(2)Å c=8.5972(9)Å
α=90° β=106.400(10)° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 2-bromobenzoate
C11H17N2O,C7H4BrO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=6.9824(2)Å b=13.2292(4)Å c=19.4903(7)Å
α=90° β=90° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 2-iodobenzoate
C11H17N2O,C7H4IO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.0101(4)Å b=13.3796(6)Å c=19.5524(6)Å
α=90° β=90° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 2-methylbenzoate
C11H17N2O,C8H7O2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.8260(10)Å b=10.320(2)Å c=12.055(3)Å
α=78.37(2)° β=78.27(2)° γ=73.83(2)°
4-(2-Methoxyphenyl)piperazin-1-ium 4-aminobenzoate
C11H17N2O,C7H6NO2
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=14.9220(10)Å b=7.6951(5)Å c=15.5600(10)Å
α=90° β=106.911(8)° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 4-nitrobenzoate
C11H17N2O,C7H4NO4
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.5174(5)Å b=7.9761(5)Å c=29.860(2)Å
α=90° β=97.322(6)° γ=90°
4-(2-Methoxyphenyl)piperazin-1-ium 3,5-dinitrobenzoate dihydrate
C11H17N2O,C7H3N2O6,2(H2O)
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.8448(6)Å b=11.4635(9)Å c=12.0747(9)Å
α=94.406(7)° β=105.075(8)° γ=93.717(7)°
4-(2-Methoxyphenyl)piperazin-1-ium 2,4,6-trinitrophenolate
C11H17N2O,C6H2N3O7
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=9.4151(5)Å b=9.8721(5)Å c=10.9572(5)Å
α=77.524(4)° β=81.360(5)° γ=81.002(5)°
4-(2-Methoxyphenyl)piperazin-1-ium hydrogen (2<i>R</i>,3<i>R</i>)-tartrate 1.698-hydrate
C11H17N2O,C4H5O6,1.698(H2O)
Acta Crystallographica Section E (2020) 76, 11 1779-1793
a=7.4790(10)Å b=7.0650(10)Å c=17.788(3)Å
α=90° β=101.58(2)° γ=90°
Clozapinium hydrogen bis(3,5-dinitrobenzoate)
C18H20ClN4,C7H3N2O6,C7H4N2O6
Acta Crystallographica Section E (2020) 76, 10 1629-1633
a=7.4102(6)Å b=24.629(2)Å c=18.4460(10)Å
α=90° β=98.478(6)° γ=90°
4-(4-Fluorophenyl)piperazin-1-ium 2-bromobenzoate 0.353-hydrate
C10H14FN2,C7H4BrO2,0.353(H2O)
Acta Crystallographica Section E (2020) 76, 8 1179-1186
a=7.2584(8)Å b=9.3470(10)Å c=13.767(2)Å
α=101.140(10)° β=95.980(10)° γ=109.440(10)°
4-(4-Fluorophenyl)piperazin-1-ium 2-fluorobenzoate monohydrate
C10H14FN2,C7H4FO2,H2O
Acta Crystallographica Section E (2020) 76, 8 1179-1186
a=6.5873(5)Å b=7.6616(6)Å c=17.3399(9)Å
α=97.842(6)° β=90.378(6)° γ=95.540(6)°
4-(4-Fluorophenyl)piperazin-1-ium 2-iodobenzoate
C10H14FN2,C7H4IO2
Acta Crystallographica Section E (2020) 76, 8 1179-1186
a=9.8892(3)Å b=11.6831(7)Å c=16.4547(9)Å
α=106.776(5)° β=93.327(4)° γ=104.874(4)°
4-(4-Fluorophenyl)piperazin-1-ium 2,4,6-trinitrophenolate
C10H14FN2,C6H2N3O7
Acta Crystallographica Section E (2020) 76, 8 1179-1186
a=16.658(2)Å b=6.6734(6)Å c=17.553(3)Å
α=90° β=117.84(2)° γ=90°
4-(4-Fluorophenyl)piperazin-1-ium 3,5-dinitrobenzoate
C10H14FN2,C7H3N2O6
Acta Crystallographica Section E (2020) 76, 8 1179-1186
a=19.8710(10)Å b=7.3420(7)Å c=26.306(2)Å
α=90° β=94.540(8)° γ=90°
<i>N</i>-{[4-(3-phenyl-4-sydnonylideneamino)-5-sulfanylidene-1<i>H</i>-1,2,4-triazol-3-yl]methyl}benzamide ethanol monosolvate
C19H15N7O3S,C2H6O
Acta Crystallographica Section E (2020) 76, 7 1057-1061
a=8.6313(6)Å b=10.8378(9)Å c=13.3840(10)Å
α=66.645(8)° β=79.287(8)° γ=85.151(8)°
<i>N</i>-({4-[3-(4-Methylphenyl)-4-sydnonylideneamino]-5-sulfanylidene-1<i>H</i>-1,2,4-triazol-3-yl}methyl)benzamide ethanol monosolvate
C20H17N7O3S,C2H6O
Acta Crystallographica Section E (2020) 76, 7 1057-1061
a=8.5631(5)Å b=11.1242(8)Å c=13.5632(9)Å
α=70.244(6)° β=76.086(7)° γ=84.058(6)°
4-(4-Fluorophenyl)piperazin-1-ium 2-hydroxy-3,5-dinitrobenzoate
C10H14FN2,C7H3N2O7
Acta Crystallographica Section E (2020) 76, 6 841-847
a=10.6829(6)Å b=13.1701(6)Å c=13.5563(7)Å
α=90° β=108.970(5)° γ=90°
4-(4-Fluorophenyl)piperazin-1-ium hydrogen oxalate
C10H14FN2,C2HO4
Acta Crystallographica Section E (2020) 76, 6 841-847
a=17.0606(6)Å b=5.7820(2)Å c=12.5815(5)Å
α=90° β=102.761(4)° γ=90°
4-(4-Fluorophenyl)piperazin-1-ium hydrogen (2<i>R</i>,3<i>R</i>)-tartrate monohydrate
C10H14FN2,C4H5O6,H2O
Acta Crystallographica Section E (2020) 76, 6 841-847
a=7.0961(4)Å b=7.4967(4)Å c=30.757(2)Å
α=90° β=90° γ=90°
3-[5-(2-Chlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-[4-(prop-2-yn-1-yloxy)phenyl]prop-2-en-1-one
C28H21ClN2O3
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.909(7)Å b=10.193(6)Å c=12.024(8)Å
α=90.94(2)° β=106.27(2)° γ=92.75(2)°
3-[3-Methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C32H24N2O3
Acta Crystallographica Section E (2020) 76, 5 683-691
a=8.8615(6)Å b=10.4973(7)Å c=13.6588(10)Å
α=79.006(3)° β=89.412(3)° γ=80.971(3)°
1-(4-Azidophenyl)-3-[3-methyl-5-(2-methylphenoxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-one
C26H21N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.8432(6)Å b=11.7441(7)Å c=12.3005(7)Å
α=114.120(2)° β=111.139(2)° γ=96.537(2)°
1-(4-Azidophenyl)-3-[3-methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-on
C29H21N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.8460(8)Å b=22.4303(18)Å c=11.0490(9)Å
α=90° β=104.157(2)° γ=90°
<i>N</i>-(4-Methoxyphenyl)piperazine
C11H16N2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.9683(7)Å b=7.9683(8)Å c=18.975(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 3,5-dinitrobenzoate
C11H17N2O,C7H3N2O6
Acta Crystallographica Section E (2020) 76, 4 488-495
a=7.4365(4)Å b=10.6276(6)Å c=13.2700(6)Å
α=92.238(4)° β=97.057(4)° γ=108.618(5)°
4-(4-Methoxyphenyl)piperazin-1-ium 2,4,6-trinitrophenolate
C11H17N2O,C6H2N3O7
Acta Crystallographica Section E (2020) 76, 4 488-495
a=8.7568(6)Å b=6.6292(5)Å c=34.024(2)Å
α=90° β=96.987(6)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-aminobenzoate monohydrate
C7H6NO2,C11H17N2O,H2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.2590(7)Å b=7.4549(9)Å c=19.269(2)Å
α=83.280(10)° β=84.7400(10)° γ=85.380(10)°
1-(4-Bromophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13BrO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=18.286(6)Å b=14.277(4)Å c=5.8489(17)Å
α=90° β=94.521(7)° γ=90°
1-(4-Chlorophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13ClO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=17.990(3)Å b=14.2529(16)Å c=5.8661(8)Å
α=90° β=94.419(4)° γ=90°
(<i>RS</i>)-3-(4-Bromophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16BrN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.1255(13)Å b=6.0426(5)Å c=21.026(2)Å
α=90° β=110.555(3)° γ=90°
(<i>RS</i>)-3-(4-Chlorophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16ClN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.0182(9)Å b=6.0579(3)Å c=20.8286(12)Å
α=90° β=110.573(2)° γ=90°
(<i>RS</i>)-3-(4-Methoxyphenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C20H19N3O2S
Acta Crystallographica Section E (2020) 76, 3 360-365
a=11.7852(15)Å b=7.5345(11)Å c=20.599(3)Å
α=90° β=93.555(4)° γ=90°
2-(4-Chlorobenzyl)-6-(4-fluorophenyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18ClFN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=15.3400(10)Å b=11.1619(7)Å c=15.3850(10)Å
α=90° β=119.480(10)° γ=90°
2-(4-Chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]-6-phenylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H19ClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=16.456(7)Å b=10.420(2)Å c=26.391(7)Å
α=90° β=90.031(12)° γ=90°
6-(4-Bromophenyl)-2-(4-chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18BrClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=9.5735(8)Å b=9.6860(9)Å c=25.644(2)Å
α=90° β=90° γ=90°
3-(3-Methyl-5-phenoxy-1-phenyl-1<i>H</i>-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one
C23H18N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.6158(5)Å b=19.8846(11)Å c=10.3773(6)Å
α=90° β=93.712(2)° γ=90°
3-[3-Methyl-5-(2-methylphenoxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-(thiophen-2-yl)prop-2-en-1-one
C24H20N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.4336(4)Å b=20.6071(9)Å c=10.5866(4)Å
α=90° β=93.106(2)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-bromobenzoate monohydrate
C11H17N2O,C7H4BrO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2004(8)Å b=7.4957(9)Å c=20.440(2)Å
α=85.080(10)° β=87.370(10)° γ=85.000(10)°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxybenzoate
C11H17N2O,C7H5O3
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.5009(8)Å b=7.9735(9)Å c=32.155(4)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxy-3,5-dinitrobenzoate
C7H3N2O7,C11H17N2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=7.5500(9)Å b=7.6489(9)Å c=32.719(6)Å
α=90° β=91.300(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogensuccinate
C11H17N2O,C4H5O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.3225(9)Å b=28.261(3)Å c=5.8228(8)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium pyridine-3-carboxylate
C11H17N2O,C6H4NO2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.2817(7)Å b=11.2905(7)Å c=30.309(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenfumarate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0690(10)Å b=28.528(3)Å c=5.8375(9)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenmaleate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0630(10)Å b=6.4956(9)Å c=26.093(3)Å
α=90° β=93.180(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium trichloroacetate
C11H17N2O,C2Cl3O2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=10.6117(11)Å b=13.8080(10)Å c=10.9137(8)Å
α=90° β=90° γ=90°
Bis(4-(4-methoxyphenyl)piperazin-1-ium) chloranilate(2-) dihydrate
C11H17N2O,0.5(C6Cl2O4),H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.1597(5)Å b=15.1434(8)Å c=10.8742(6)Å
α=90° β=102.067(5)° γ=90°
(<i>E</i>)-2-Ethyl-<i>N</i>-(4-nitrobenzylidene)aniline
C15H14N2O2
Acta Crystallographica Section E (2018) 74, 8 1071-1074
a=7.6419(7)Å b=11.8889(13)Å c=14.8082(16)Å
α=90° β=90° γ=90°